Drug Trial Radar · NCT04615949
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
90
Actual
Start
Apr 30, 2021
Primary completion
Nov 30, 2022
Study completion Nov 30, 2022
Sponsor
- Lead sponsor
- Cardiol Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
Conditions
- COVID-19
- Cardiovascular Diseases
- Cardiovascular Risk Factor
Interventions
Cannabidiol, pharmaceutically produced with < 5 ppm THCDrug
CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
PlaceboDrug
Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of All-cause Mortality, Requirement for ICU Admission and/or Ventillatory Support and Cardiovascular ComplicationsTime frame: 28 days post randomization
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
Valleywise Health Medical Center
Phoenix, Arizona
JY Research Institute
Cutler Bay, Florida
Westchester General Hospital
Miami, Florida
University of South Florida
Tampa, Florida
Prairie Education and Research Cooperative
Springfield, Illinois
University of Texas Health Science Center
San Antonio, Texas
Baylor Scott & White Health - Temple
Temple, Texas
Complexo Hospitalar de Niteroi- Centro de Pesquisa Clinica
Rio de Janeiro, Brazil
Science Valley Research Institute
Campo Largo, Paraná, Brazil
Universidade Estadual de Maringa
Maringá, Paraná, Brazil
Hospital São Lucas PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Irmandade Santa Casa de Misericórdia
Porto Alegre, Rio Grande do Sul, Brazil
Núcleo de Ensino e Pesquisa do Instituto Mário Penna
Conjunto ACM, Santa Maria, Brazil
Fundação Pio XII - Hospital de Amor Barretos
Barretos, São Paulo, Brazil
IPECC-Instituto de Pesquisa Clínica de Campinas
Campinas, São Paulo, Brazil
Instituto do Coração do HCFMUSP
Cerqueira César, São Paulo, Brazil
SVRI- Irmandade de Santa Casa de Misercordia de Santos
Jabaquara, São Paulo, Brazil
Science Valley Research Institute
Santo André, São Paulo, Brazil
Fundação Faculdade Regional de Medicine de Sao Jose do Rio Preto (SJRP)
São José do Rio Preto, São Paulo, Brazil
TecSalud
Monterrey, Nuevo León, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.